The purpose of this study is to assess the safety and preliminary effectiveness of an investigational treatment in which a patient’s immune cells are altered in a laboratory and given back to the patient with the hope of provoking an immune response against synovial sarcoma.
NY-ESO-1 is a protein found on many synovial sarcomas. In this study, some of a patient’s T cells (a type of white blood cell) will be removed and modified with a gene that makes them recognize sarcoma cells containing NY-ESO-1. This approach is called “T-cell receptor gene therapy.”
Patients will first have chemotherapy with cyclophosphamide and fludarabine. They will then receive the NY-ESO-1-modified T cells. Researchers will determine if this therapy is safe and see if the altered T cells can kill synovial sarcoma cells.